Biogen Inc. buy Royal Bank of Canada
Start price
12.02.24
/
50%
€226.20
Target price
12.02.25
€351.83
Performance (%)
-43.30%
End price
13.02.25
€128.25
Summary
This prediction ended on 13.02.25 with a price of €128.25. The BUY prediction by Royal_Bank_of_Canada for Biogen Inc. performed very badly with a performance of -43.30%. Royal_Bank_of_Canada has a follow-up prediction for Biogen Inc. where he still thinks Biogen Inc. is a Buy. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Biogen Inc. | 1.379% | 1.379% | -48.912% |
| iShares Core DAX® | -0.081% | -1.435% | 28.742% |
| iShares Nasdaq 100 | -0.201% | 1.543% | 3.702% |
| iShares Nikkei 225® | 1.465% | 1.838% | 2.749% |
| iShares S&P 500 | 0.215% | 1.237% | 4.241% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Royal Bank of Canada from $363.00 to $379.00. They now have an "overweight" rating on the stock.
Ratings data for BIIB provided by MarketBeat
In the thread Trading Biogen Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten